Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
Engineered Salmonella secreting heterologous bacterial flagellin suppress tumor growth by activating intratumoral macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
From The microbiome and human cancer (2021) · cites this paper as [152]
Citations
Cites
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“INTRODUCTION Abnormal blood vessels and hypoxic and necrotic regions are universal features of solid tumors (1, 2).”
BackgroundKigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130 · cited 1×
“The engrafted MC38 tumor tissues were removed from C57BL/6 WT mice 24 hours after induction of FlaB and triple-stained with CD45, F4/80, and CD206 (to detect M2-type macrophages) or with CD45, F4/80, and CD86 (to detect M1-type macrophages) (32, 33).”
MethodTargeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041 · cited 1×
“TLR4, TLR5, and MyD88 knockout mice with a C57BL/6 genetic background were described previously (47, 48).”
MethodMolecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980 · cited 10×
“The in vitro stimulation of cancer cells with FlaB did not increase phosphorylation of NF-kB p65 (fig.”
BackgroundInfluentialThe Isolation and Characterization of Murine Macrophages
Zhang, X., Goncalves, R., & Mosser, D. M. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im1401s83 · Cited by 1,536 · cited 1×
“Cell preparation and FACS analysis Peritoneal macrophages were isolated from specific pathogen–free C57BL/6 male mice, as described previously (50).”
MethodToll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 1×
“Because the background signals in experimental groupswere different, whichmay be due to different degrees of cell injury resulting from the different modes of treatment (PBS, empty Salmonella, and FlaB-secreting Salmonella), we adjusted gating parameters for the FACS analysis of different groups (51, 52).”
MethodTherapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Because of accumulating reports that activating various TLRs resulted in antitumor effects (31, 37–41), many TLRspecific agonists are currently being investigated for tumor immunotherapy (37).”
BackgroundBiswas, S. K. (2006) · Blood · doi:10.1182/blood-2005-01-0428 · Cited by 696
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“VNP20009, an attenuated strainof Salmonella typhimurium with purI and msbB gene deletions, was safely administered to patients with metastatic melanoma and renal cell carcinoma in a phase 1 study, where substantial tumor colonization was observed (11, 12).”
Research works printed but not linked: 1
- 10.1200/jco.2002.20.1.142 · DOI · Paper page
Cited by
Items 501–600 of 627
From dysbiosis to tumorigenesis: microbiome-derived metabolites as emerging cancer biomarkers
Sanjana, A., & Viswanathan, P. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1843755 · Cited by 2
Kong, Z., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1891408 · Cited by 2
“Leveraging this property, engineered bacteria have been developed as intratumoral bioreactors that continuously produce therapeutic payloads and promote tumor regression (120 – 123).”
Jazeela, K., Chakraborty, A., Kotian, A., Aditya, V., Kumar, B. K., Rai, P., Karunasagar, I., & Deekshit, V. K. (2021) · Archives of Microbiology · doi:10.1007/s00203-021-02243-4 · Cited by 2
“Typhimurium defective in the ppGpp synthesis (ΔppGpp: depletion of relA and spoT) exhibited the up regulation of certain tumor supressing cytokine genes like IL-1ß, IL-18 and TNF-α and also triggered the production of NLRP3, IPAF (inflammasome coding genes) in MC38 and CT26 in colon cancer murine models (Zheng et al.…”
BackgroundMicrobiome therapeutics for the cancer management
Punetha, A., & Punetha, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00012-4 · Cited by 2
Revamping Hepatocellular Carcinoma Immunotherapy: The Advent of Microbial Neoantigen Vaccines
Liang, J., Liao, Y., Tu, Z., & Liu, J. (2024) · Vaccines · doi:10.3390/vaccines12080930 · Cited by 2
“For instance, Vibrio vulnificus flagellin B (FLAB) was used to activate immune cells such as macrophages and neutrophils against cancers via the TLR4 pathway [77].”
MethodRecent Advances in Bacterium‐Based Therapeutic Modalities for Melanoma Treatment
Khan, M., Dong, Y., Ullah, R., Li, M., Huang, Q., Hu, Y., Li, Y., & Luo, Z. Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401076 · Cited by 2
Engineered microbes for cancer immunotherapy
Brennan, A. M., Sokolovska, A., Li, N., & Isabella, V. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00002-4 · Cited by 2
Molecular Farming and Anticancer Vaccine
Ratre, Y. K., Mehta, A., Shinde, S., Sinha, V., Soni, V. K., Sonkar, S. C., Shukla, D., & Vishvakarma, N. K. (2023) · Wiley eBooks · doi:10.1002/9781119874096.ch17 · Cited by 2
Luo, J., He, L., Guo, Y., Wang, J., Liu, H., & Li, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910285 · Cited by 2
“…to enhance cancer suppression in numerous cancer models; the overexpression of heterologous flagellin was proved to activate infiltrated immune cells in TMEs and promote the polarization of the M2 phenotype macrophage into an M1 phenotype, thus inhibiting cancer growth in colon cancer models [21].”
BackgroundMethodQuintero, D. A., Carrafa, J., Vincent, L., Lee, H. J., Wohlschlegel, J. A., & Bermudes, D. G. (2018) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1808.08036 · Cited by 2
Biological Modulation of the Treg:Teff Ratio: From Immunosuppression to Immunoactivation
Yang, X., & Scott, M. D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92038 · Cited by 2
The Gut and Urinary Microbiota: A Rising Biomarker in Genitourinary Malignancies
Pederzoli, F., Murdica, V., Salonia, A., & Alfano, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80546-3_19 · Cited by 2
Advances in the Application of Bacteria in Tumor Therapy
张, 媛. (2024) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2024.142024 · Cited by 2
Programmable cancer treatments: Engineering biology approaches for living cures
Biarnes-Carrera, M., Sevko, A., Glanville, N., & Deban, L. (2024) · Engineering Biology · doi:10.1049/enb2.12032 · Cited by 1
“Examples of extracellular payloads include cytokines [107, 110–113], antibody ‐ like molecules [108, 114] and immunostimulatory proteins (e.g. FlaB [57]).”
BackgroundImaging of inflammation and infection
Liu, J., & Zheng, J. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95223-1.00012-6 · Cited by 1
Self-citationBacteria-Based Approach to Cancer Therapy
Bình, T. D., Bokorová, R., & Yamada, T. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_337 · Cited by 1
A Microrobotic System Based on Engineered Bacteria for Targeted Self‐Driven Photodynamic Therapy
Jin, K., Yu, L., Zhang, Y., Niu, L., Huang, Y. B., Zhang, Y., & Wu, Y. (2024) · Angewandte Chemie · doi:10.1002/ange.202414347 · Cited by 1
Finn, J., Kessler, E., Lass, M., Oviedo-Bermudez, E., & Kurt, R. A. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.105050 · Cited by 1
Cytrynbaum, E. G., & McClean, M. N. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115740 · Cited by 1
Wang, L., Wang, Y., Lei, R., Wang, H., Liang, S., Yao, Y., Zhao, C., Rui, X., Ji, J., & Wu, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114548 · Cited by 1
Advancements in technology for developing recombinant live biotherapeutics
Verma, J. K., & Paul, D. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.006 · Cited by 1
Nandan, A., & Datta, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5378-5_1 · Cited by 1
Baliou, S., Tzatzarakis, M. N., Tsantes, A. G., Vakonaki, E., Ιωάννου, Π., Michalis, K., Hatzidaki, E., Pelagiadis, I., Stiakaki, E., & Tsatsakis, A. M. (2026) · Diseases · doi:10.3390/diseases14020080 · Cited by 1
“Initially, William B. Coley discovered that several bacteria can selectively enter tumors and elicit immune responses [41,42].”
Liu, X., Cai, R., Meng, Y., Xu, Y., Wang, B., Liu, M., Wang, Y., Yu, Y., Lu, C., Wei, Y., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105220 · Cited by 1
Qiu, Y., Liu, Y., Chen, S., Liu, Y., Yu, X., Yang, X., Zhang, Y., & Zhu, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04300-w · Cited by 1
Yang, W., Li, A., Dong, B., Feng, X., & Jiang, F. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108902 · Cited by 1
Zhang, Z., Jiang, X., 黄文军, 杨小猛, & Li, F. F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1790215 · Cited by 1
Immunomodulatory microbials for cancer immunotherapy: A mini review
Hou, Y., Shi, Y., & Yang, Y. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112912 · Cited by 1
Geng, F., Yue, L., Du, M., Jin, J., Zhang, Q., Hu, W., Hao, N., Liu, S., Jiang, P., & Pan, X. (2026) · Biotechnology Journal · doi:10.1002/biot.70243 · Cited by 1
“For example, Salmonella typhimurium has been engineered to express flaB, and Escherichia coli Nissle 1917 has been modified to secrete TNF-α nanobodies or express cytokines such as IL-2, IL-18, and CCL21, thereby remodeling tumor immunity [14–17].”
Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology
Liu, X., Zhang, H., Du, R., Liu, Z., Ren, Y., & Yang, X. S. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683171 · Cited by 1
“24,25 Collectively, these mechanisms not only amplify innate immune responses but also provide essential signals for initiating adaptive immunity.”
Wang, J., & Jiang, R. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.03 · Cited by 1
The intratumoral microbiome as an emerging hub in cancer pathogenesis and precision oncology
Sun, J., Song, S., Luo, S., Qing, F. A. N., Li, X., Liu, H., & Wu, G. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02762-y · Cited by 1
An engineered probiotic for diagnosis and mucosal healing in inflammatory bowel disease
Zhao, Y., Sun, Y., Zhu, X., Hu, W., Chen, S., Peng, G., Yang, S., Ma, D., Mao, X., Yi, S., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118171 · Cited by 1
Self-citationYoo, S. W., Kim, H.-S., Min, J., & Lee, C. (2019) · Endoscopic Microscopy · doi:10.1117/12.2509530 · Cited by 1
Self-citationMicrobial-Based Cancer Therapy: Diagnostic Tools and Therapeutic Strategies
Malik, S. S., Masood, N., Fatima, I., & Kazmi, Z. (2019) · Microorganisms for sustainability · doi:10.1007/978-981-13-8844-6_3 · Cited by 1
Faintuch, J., & Faintuch, J. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815249-2.00046-4 · Cited by 1
Genetically engineered microbes for sustainable therapies
Sharma, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820528-0.00009-0 · Cited by 1
Bacteria-based nanosystems for enhanced antitumor therapy
Han, Y., Fan, M., Han, D., Ge, K., Chang, J. K., & Zhang, J. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1991-y · Cited by 1
Theranostic Approaches Using Live Bacteria
Min, J., Duong, M. T.-Q., Thangam, R., You, S.-H., & Kang, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00056-9 · Cited by 1
Self-citationVisualized Cancer Immunotherapy with Engineered Salmonella typhimurium
Sun, Y., & Zheng, J. H. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2441-8_15 · Cited by 1
Self-citationModulation of tumor environment in colorectal cancer – could gut microbiota be a key player?
Mendes, A. D., Vicente, R. S., Vitorino, M. M., Silva, M., & Costa, D. A. (2022) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2022.1021050 · Cited by 1
Designer Microbes: Oncotherapy Approach
Das, J. K., & Arunima, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_10 · Cited by 1
Microbes used as anticancer agents and their potential application in biomedicine
Bhardwaj, S., & Bhatia, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90113-0.00010-9 · Cited by 1
Exploiting the Powerful Anti-tumor Effects of Salmonella Typhimurium: Systematic Review
Taheri, S. A., Norouzi, M., Monirvaghefi, A., Najafi, F., Meshkinshahr, A. A., Aghili, S., Behzad, G., Khatibi, D. M., Kasaei, B., & Batmani, A. (2023) · Journal of Lab Animal Research · doi:10.58803/jlar.v2i5.30 · Cited by 1
The Microbiome and Innate Immunity: Role in the Tumor Microenvironment
Bueno-Urquiza, L. J., Martínez-Barajas, M. G., Pereira-Suárez, A. L., Villegas‐Mercado, C. E., & Bermúdez, M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_367 · Cited by 1
TIME Is Critical for Oncolytic Viral Therapies Against Solid Cancers
Kumar, V., & Stewart, J. H. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_440 · Cited by 1
Editorial: Microorganisms and their derivatives for cancer therapy
Zhang, Y., Rodrigues, L. R., Cao, Z., & Li, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1137341 · Cited by 1
“, 2019) and flagellin B (Zheng et al., 2017), have been reported to trigger strongly non-specific immunotherapy responses in cancer.”
BackgroundMolecular diagnosis of infectious disease and cancer via synthetic biological methods
Lim, B. (2021) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-eookpdmxy · Cited by 1
Therapeutic cancer vaccines: navigating clinical translation and multimodal synergy
Chu, T.-H., Huynh, T. L., & Phuong, L.-T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1818121
Papers of note in Science Translational Medicine 9 (376)
Ferrarelli, L. K. (2017) · Science Signaling · doi:10.1126/scisignal.aam9533
Häfner, S. J. (2017) · Microbes and Infection · doi:10.1016/j.micinf.2017.04.005
Actinobactérias da Antártica produtoras de compostos anticâncer
da Silva, L. J. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.11.2019.tde-17012019-165858
Bermudes, D. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11362-5
dos Reis, E. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2020.tde-16122019-104755
Jain, D., Sood, A., Takenaka, H., Sano, M., So, S., Tomita, I., Kanayama, N., & Jain, A. K. (2021) · Environmental Disease · doi:10.4103/ed.ed_27_20
Monocytes mediate Salmonella Typhimurium-induced tumour growth inhibitionPreprint
Johnson, S. A., Ormsby, M. J., Wessel, H. M., Hulme, H., Bravo‐Blas, A., McIntosh, A., Mason, S. M., Coffelt, S. B., Tait, S. W. G., Mowat, A. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.13.092858
“…much evidence to support the anti-tumour effects of bacteria such as Salmonella enterica serovar Typhimurium, Escherichia coli, Listeria monocytogenes, BCG and others in in vivo tumour models (Crull et al., 2011; Lizotte et al., 2014; Morales et al., 1976; Stern et al., 2015; Zheng et al., 2017).”
BackgroundInfluentialHe, X. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87403
Microbiome as a therapeutic target
Moiseenko, F. V. (2022) · Practical oncology · doi:10.31917/2303160
Exploring the Potential of Microbial Engineering: The Prospect, Promise, and Essence
Patra, S. D., Arunima, A., & Suar, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_1
Affordable Therapeutics Through Engineered Microbes
Sahoo, S., & Misra, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_15
Genetiği Değiştirilmiş Probiyotikler
Çıldır, Ö. Ş. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub358.c1516
Redefining Cancer Battlefields: Novel CAR T-cell Therapies in Solid Tumor Warfare
Yeh, A. C., & Markey, K. A. (2024) · The Hematologist · doi:10.1182/hem.v21.1.202413
Research on Nano-drug Delivery System in Tumor Immunotherapy
Fang, Z. (2024) · International Journal of Frontiers in Medicine · doi:10.25236/ijfm.2024.060204
Chapter 4 Engineering microbial cells for cancer
Akboğa, D., Doğruer, A., Albayrak, D., Shahid, G. B., & Şeker, U. Ö. Ş. (2024) · De Gruyter eBooks · doi:10.1515/9783111329499-004
Non-lactic Acid Bacteria and Other Novel Probiotics
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65455-8_7
Designer Probiotics and Postbiotics
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_25
Probiotic Interventions in Cancer
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_11
Engineering Microbes for Health and Therapeutic Applications
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_21
Targeting engineered bacteria to improve cancer immunotherapy
Dash, A., Bahuguna, S., & Das, J. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13827-0.00004-4
КЛИНИЧЕСКИЕ ОСОБЕННОСТИ ИНФЕКЦИИ, ВЫЗВАННОЙ БАКТЕРИЕЙ VIBRIO VULNIFICUS
Улюкин, И. М., Орлова, Е. С., & Сечин, А. А. (2025) · Флагман науки · doi:10.37539/2949-1991.2024.23.12.011
Cellular Drug Delivery Vehicle
Li, J., Liu, Y., & Hu, X. (2025) · Springer eBooks · doi:10.1007/978-981-19-8930-8_8
Insights on the Role of the Microbiome in Influencing Cancer Risk
Das, J., Padhan, B., Sadhukhan, A., Halder, R., Purohit, S., & Aich, T. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-2165-3.ch005
Microorganisms as Vehicles for Targeted Drug Delivery: Applications and Prospects
Dong, X. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.pj25375
Synthetic biology and genetic engineering in pharmaceutical bioprospecting
Kant, S., Roy, S., & Sarkar, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33032-2.00019-8
Iwata, S., Yamasita, N., Asukabe, K., Sakari, M., & Miyako, E. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2599562
Immune Mechanisms of Microbial Cancer Therapy
Yam, A. (2023) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/25332
がん治療用生菌製剤開発のための菌種選択および動態評価に関する研究
Nomura, S. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.14989/doctor.k23146
Liu, L.-N., Chen, C., Xin, W.-J., Li, Q., Han, C., & Hua, Z.-C. (2024) · Figshare · doi:10.6084/m9.figshare.26682463
Xu, Y., Wu, Y., Hu, Y., Xu, M., Liu, Y., Ding, Y., Chen, J., Huang, X., Wen, L., Li, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26580812
Hybrid nanosystems for the delivery of therapeutic agents as tretament for complex diseases
Moreno-Zafra, V. (2021) · Library Open Repository (Universidad Complutense Madrid)
Maksymowicz, P. (2017) · Jagiellonian University Repository (Jagiellonian University)
The direct and indirect effects of attenuated salmonella typhimurium on intestinal tumour epithelium
Mackie, G. M. (2024) · University of Birmingham Institutional Research Archive (University of Birmingham)
Exploring the impact of probiotics and tumor-resident commensal bacteria on cancer
McPherson, A. C. (2024) · D-Scholarship@Pitt (University of Pittsburgh)
Charakterystyka systemu flagelinowego bakterii gram-ujemnych
(2017) · Homo Politicus (Academy of Humanities and Economics in Lodz)
An enhanced phage-derived lytic platform for programmable autolysis in E. coliPreprint
Siciliano, V., Cassella, L., Petrosino, A., Liguori, F., Cannarsa, M. C., Frangipane, G., Mollo, V., & Leonardo, R. D. (2026) · Research Square · doi:10.21203/rs.3.rs-8418738/v1
Jakka, S. R., & Mugesh, G. (2026) · Angewandte Chemie · doi:10.1002/ange.202525502
Huang, Y., Piao, L., Zhang, H., & Liu, X. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201185
“20 To augment its therapeutic potential, the Δ ppGpp strain has been genetically engineered to express various anticancer agents, including Noxa, 21 FlaB, 22 and ClyA, 18 within the TME.”
Zhang, S., Wang, J., Gao, S., Gao, C., Chen, L., & Qi, P. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01858-4
Development of lipid-based nanoparticles for chemo-attraction and targeting of Helicobacter pylori
Nguyen, V. H. (2022) · theses.fr (ABES) · doi:10.70675/04253af0zeb4dz4b9az9649z297af4a9c40b
Self-citationMicrobial therapeutic agents as a new frontier in tumor-targeted drug delivery
Islam, T., Ali, S., Almalki, M., & Rabbee, M. F. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108366
Hadjigol, S., Shah, B. A., Yazdani, N., & O’brien-simpson, N. M. (2026) · Cells · doi:10.3390/cells15100855
The role of engineered microbes in immune modulation across cancer, autoimmunity, and infection
Al-Ewaidat, O. A., & Naffaa, M. M. (2026) · Microbes & Immunity · doi:10.36922/mi025520142
Smail, S. W., Flaih, A. H., Ismail, B. A., Ahmed, A. A., Bapir, A. A., Qadir, F. A., & Janson, C. (2026) · Immuno · doi:10.3390/immuno6020034
“Additionally, tumor antigens released by bacteria-mediated tumor lysis can be presented by APCs to trigger an adaptive immune response [18].”
Inorganic nanomaterials empowering bacteria: a new paradigm for biomedical applications
Chen, Z., Hou, X., Wang, S., Qi, G.-M., Ma, G., Wei, W., & Zheng, D. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00687f
Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy
Li, Y. C., Zhang, H. F., Feng, Y., Fang, K., Wang, Y., Zhou, Y., Sun, T., & Xu, J. (2026) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0769
“This combination strategy showed significant anti-metastatic effects in mouse models by reprogramming the TIME and stimulating innate and adaptive immunity 115,116 .”
Suppression of Salmonella Effectors with CRISPRi Controls the Immune Response to Bacterial Therapies
Deshpande, C. P., Khanduja, S., Rondthaler, S. N., Andrews, L. B., & Forbes, N. S. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00041
The Microbial Conductor: Orchestrating Cancer Hallmarks through the Intratumoral Microbiome
Hamid, R. T., Ismael, D. H., Shihab, R. N., & Mohammed, N. (2026) · Iraqi Journal of Cancer and Medical Genetics · doi:10.29409/s5c44z69
Wang, S., Wang, W., Zhang, Y., Li, Y., Zhang, Q., Yuan, J., Liu, T. T., Sun, J. K., Jiang, X., & Sun, B. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179264
Metadata
- Authors
- Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., Choy, H. E., Lee, S. E., Rhee, J. H., & Min, J.-J.
- Affiliations
- Chonnam National University (KR)
- City Of Hope National Medical Center (US)
- Department of Nuclear Medicine, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Corresponding author
- Rhee, Joon Haeng
- Min, Jung-Joon
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-08
- Volume
- 9
- Issue
- 376
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2586223583
- Cited by
- 588
- References
- 54
- Citations by year
- 2026: 76 · 2025: 81 · 2024: 85 · 2023: 73 · 2022: 71 · 2021: 65 · 2020: 55 · 2019: 34 · 2018: 30 · 2017: 18
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- KRIBB Repository (submittedVersion)
- Funders
- Pioneer Research Center Program (2015M3C1A3056410)
- Bio & Medical Technology Development Program (NRF-2014M3A9B5073747)
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
- NRF (2012-0006072)
- Ministry of Health and Welfare, Republic of Korea (HI14C0187)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunotherapy, Salmonella typhimurium, tumor-targeting bacteria, intratumoral macrophages, M1 macrophage polarization, TLR ligands
- MeSH terms
- Animals, Colonic Neoplasms, Flagellin, Genetic Engineering, Humans, Immunotherapy, Macrophages, Male, Mice, Inbred C57BL, Mice, Nude, Neoplasm Metastasis, Neoplasms, Phenotype, Salmonella typhimurium, Colony Count, Microbial, Signal Transduction, Cell Polarity, Xenograft Model Antitumor Assays, HCT116 Cells, Toll-Like Receptor 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.